Social Network
Pfizer begins Phase 2/3 study for COVID-19 oral antiviral in exposed adults
September 28 2021, 08:00
Pfizer initiated a Phase 2/3 study of an investigational oral antiviral with a low dose of ritonavir to prevent COVID-19 illness, the company announced Monday.
Source: FOX News
Back to news
Related news
Family of victim and survivors of Indianapolis FedEx mass shooting file lawsuit against gun magazine manufacturer and distributors
Tennessee Air National Guardsman applied to be a hitman online, the FBI says. It was a spoof website and now he's facing charges
Fulton County, Georgia, jail leadership resigns after inmate's death and accusations of unsanitary conditions
Big-box stores could help slash emissions and save millions by putting solar panels on roofs. Why aren't more of them doing it?
Not only is Lake Powell's water level plummeting because of drought, its total capacity is shrinking, too
Boulder, Colorado suspected terror attack suspect Mohamed Sabry Soliman faces murder, assault, other charges
Exercise program reduces common cancer recurrence and boosts survival
Second lady's 2025 summer reading challenge targets declining literacy scores among students
Common supplements and medications could cause liver damage, studies show
Family of victim and survivors of Indianapolis FedEx mass shooting file lawsuit against gun magazine manufacturer and distributors